Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy May 07, 2026 5:00 pm EDT

https://www.capricor.com/investors/news-events/press-releases/detail/343/capricor-therapeutics-takes-legal-action-to-protect-patient?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-8hdMeesv3ft7-e1jERMpQF3r_WU8g9UFTge46bXH25Ga0Yzrh4Ejg20p1k_LitnNh8OxdasqWP_e974aq88bfsuqPyaw&_hsmi=417864713&utm_content=417864713&utm_source=hs_email Capricor sues partner over Duchenne therapy launch Capricor Therapeutics is suing its Japanese partner Nippon Shinyaku and subsidiary NS Pharma, arguing the companies botched launch preparations for deramiocel, the biotech’s closely watched Duchenne muscular dystrophy cell therapy. Capricor says the companies also created a pricing structure that could make the treatment financially inaccessible for many patients. The lawsuit claims the distribution agreement contains a “fundamental pricing flaw” tied to Medicare reimbursement rules that would eventually force providers to administer the therapy at a loss. “I have spent nearly two decades building Capricor with one goal in mind: making Deramiocel available to treat these boys,” Capricor CEO Linda Marbán said in a statement. “I know what every additional month of delay costs them, because I know what is happening inside their muscles when they cannot be treated. There is no version of this case in which I am willing to watch NS Pharma’s inaction take that away from them.” In a statement, Nippon Shinyaku said it had not been served with the complaint yet. It added, however, "We are confident that both Nippon Shinyaku and NS Pharma have responded appropriately and sincerely to ensure treatment reaches DMD patients after approval. While we recognize that Capricor’s claims lack merit, we remain open to discussions with Capricor to maximize the value of" deramiocel.